BioMedNewsBreaks – MRVL Pet Pharmaceuticals(TM) Corp. to Collaborate with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products

March 17, 2021 09:33:27

MRVL Pet Pharmaceuticals(TM), a life sciences and technology company focused on the animal health sector, today announced its entry into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. According to the update, renowned veterinary expert Dr. Albert Ahn was appointed as the chief researcher of the clinical trial that launched on Jan. 27, 2021, and is expected to consist of three phases and run until Dec. 30, 2022. Altran’s AVP of Regulatory Affairs, Quality and Compliance, Deborah Cenci, was appointed as clinical trial manager. “Dr. Ahn and I are excited about this groundbreaking and innovative line of global non-invasive therapeutic solutions for companion pets. After 30 years of combined life sciences experience and over 360 Rx Drug approvals and launches, we are extremely confident that MRVL will not only obtain regulatory approval but will also become a global leader in the industry,” Cenci said in the press release. “We feel that MRVL will fulfill an important unmet need in veterinary oncology and arthritis for companion pets, with an initial focus on mass cell tumor for canines and lymphoma cancers for feline pets.”

To view the full press release, visit

About MRVL PET Pharmaceuticals(TM) Corp.

MRVL PET Pharmaceuticals is a life sciences and technology company focused on the animal health sector with a primary mission of developing and marketing its companion animal products to the retail and veterinary markets. MRVL is developing products targeting canine and feline cancer and arthritis for CVM/FDA approval as well as launching a nutraceutical formulation for pet immune and joint support. MRVL has entered into an agreement to acquire MRVL Island Ventures Limited (“MRVL Island”), which is expected to close imminently. MRVL Island is the holder of an exclusive license to manufacture, use and sell its proprietary Blue Scorpion venom and Blue Scorpion Peptide CTX throughout North America, Europe and the United Kingdom. For more information, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork